Net Profit of Estithmar Holding Increases by 20% to QAR 422 Million, Revenues Rise by 44% to Reach QAR 4.2 Billion
Financial Results Announcement for the FY 2024
Estithmar Holding Q.P.S.C. announced its financial results for the year ended December 31, 2024, reporting a 44% increase in revenues, reaching QAR 4.2 billion, compared to QAR 2.9 billion in 2023. The gross profits of the company reached QAR 1 billion, up from QAR 801 million in 2023, reflecting a 27% increase. The company also achieved earnings before interest, tax, depreciation, and amortization (EBITDA) of QAR 742 million. The results showed a 20% rise in the company’s net profit compared to 2023, reaching QAR 422 million. Earnings per share also increased by 17% from 2023, reaching QAR 0.119 per share.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213715874/en/
Net Profit of Estithmar Holding Increases by 20% to QAR 422 Million, Revenues Rise by 44% to Reach QAR 4.2 Billion (Graphic: AETOSWire)
The 20% growth in net profit is attributed to the increase in the company’s revenues, which were primarily driven by the contracting and healthcare clusters. The contracting cluster expanded in executing and delivering projects efficiently in the Kingdom of Saudi Arabia. The healthcare cluster contributed to the rise in 2024 revenues, driven by the sustainable performance growth of The View Hospital in Qatar, and the expansion of the cluster through the subsidiary Apex Health, which signed management and operation agreements for several hospitals. A set of measures taken in the ventures cluster has also contributed to restructuring the business model and increasing revenues.
The financial results for 2024 reported a 25% increase in assets, resulting from the new projects added to Estithmar’s portfolio. The results also revealed a current liquidity ratio of 1.22.
The Board of Directors of Estithmar Holding recommended a dividend distribution equivalent to 10% of the capital, with 1 free share for every 10 shares.
For more information: Estithmar Holding - Legacy of Excellence.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213715874/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Momentum Recognized as a Clutch Global Honoree and Champion for Fall 20259.12.2025 17:09:00 CET | Press release
HTEC Momentum (formerly Momentum Design Lab), HTEC’s research, product design, management and innovation arm, has earned two of Clutch’s highest distinctions—Global Award honoree and Clutch Champion—reaffirming its ninth straight year as the platform’s top-rated UX agency worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209358771/en/ HTEC Momentum Recognized as a Clutch Global Honoree and Champion for Fall 2025 The Clutch Global Awards honorees are selected based on demonstrated industry expertise and exceptional delivery—evaluated through thousands of verified client reviews published on Clutch. Clutch’s rigorous, case-study-driven review process includes extensive verification to ensure the authenticity and depth of each submission. These distinctions further underscore HTEC Momentum’s position as a top-rated leader in UX strategy, design, and user research, reflecting the consistent satisfaction of our clients
Onego Bio Launches “The Power of Trichoderma reesei” Series to Showcase Innovation, Scale, and Real-World Applications9.12.2025 17:00:00 CET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein with precision fermentation*, today announced the launch of a new expert series titled “The Power of Trichoderma reesei: Building the Future with Fungi.” This multi-part initiative reveals the full potential of Trichoderma reesei, the microbial platform behind Onego’s Bioalbumen®, by spotlighting its scientific strengths, industrial scale, and practical performance across food manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209632524/en/ Headshot of Dr. Sharief Barends The first session, “Why Trichoderma reesei is Precision Fermentation’s Quiet Workhorse,” will be held on December 18, 2025, featuring Dr. Sharief Barends, Head of Research Leiden (Netherlands) and Head of Fungal Genetics at IFF, and Dr. Christopher Landowski, Co-Founder and Chief Technology Officer at Onego Bio. Together, they will explore the research legacy, strengths, and
Guinea Emerges as West Africa's New Digital Transformation Powerhouse9.12.2025 16:53:00 CET | Press release
The Republic of Guinea has reached a decisive turning point as a regional digital power. By hosting the Transform Africa Summit 2025, becoming the first francophone nation to receive this major continental event since its creation in 2013, Guinea confirmed the emergence of Conakry as a new digital innovation hub in West Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209780892/en/ Rose Pola Pricemou, Minister of Posts, Telecommunications and Digital Economy of the Republic of Guinea (Photo: AETOSWire) The numbers break all records: over 7,000 participants from 79 countries, including 47 ministers, 1,552 government representatives, 584 business leaders, over 590 start-ups, and 14 MoUs signed. Never before in the history of the Transform Africa Summit has such mobilisation been accomplished. This unprecedented turnout demonstrates international confidence in Guinea's ability to lead Africa's digital transformation ch
Rapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel Occlusions9.12.2025 16:47:00 CET | Press release
The milestone reflects growing evidence for distal-specific thrombectomy solutions and is reinforced by interim findings that confirmed no safety concerns with TIGERTRIEVER 13. Rapid Medical™, a leading developer of active endovascular devices, announces the completion of patient enrollment in the DISTALS Trial, a multicenter randomized study assessing the TIGERTRIEVER 13™ device in patients with distal medium vessel occlusions (DMVO) in acute ischemic stroke. “DMVO strokes represent up to 40% of ischemic strokes and can cause significant disability, yet their treatment has remained uncertain. Recent neutral results from ESCAPE-MEVO and DISTAL made one thing clear: distal thrombectomy requires devices and trials specifically engineered for distal vessels,” said Dr. Jeffrey Saver of UCLA in California, Principal Investigator of DISTALS. “TIGER 13 and DISTALS bring that dedicated design. Completing enrollment is a major step toward evidence that can truly advance care for these patients.
Suzano Launches Nature Strategy and Reinforces the Strategic Importance of Biodiversity Conservation to the Business9.12.2025 16:41:00 CET | Press release
This initiative brings together science and stakeholder collaboration to drive solutions to biodiversity challenges at scale Suzano, the world’s largest pulp producer, has launched its Nature Strategy, reaffirming the company's commitment to biodiversity and how it guides decision-making within the business. Suzano's operations depend directly on nature, and the company recognizes that its longevity and ability to innovate are intrinsically linked to the health of ecosystems. Therefore, nature occupies a significant strategic role in the business’ vision. The science-led Nature Strategy, developed in collaboration with IUCN, is guided by the mitigation hierarchy: avoid, reduce, restore and transform. This approach enables the prevention of impacts, the minimization of risks, and the promotion of ecosystem regeneration. With support from IUCN, Suzano has pioneered the use of the STAR metric – a tool that enables the company to map sensitive areas within the territories where it operates
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom